Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $11.1 million.

  • Century Therapeutics' Accumulated Expenses fell 1779.98% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 1779.98%. This contributed to the annual value of $17.5 million for FY2024, which is 7204.65% up from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Accumulated Expenses is $11.1 million, which was down 1779.98% from $11.7 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Accumulated Expenses ranged from a high of $17.5 million in Q4 2024 and a low of $4.8 million during Q1 2022
  • For the 4-year period, Century Therapeutics' Accumulated Expenses averaged around $9.9 million, with its median value being $9.9 million (2023).
  • In the last 5 years, Century Therapeutics' Accumulated Expenses soared by 7204.65% in 2024 and then crashed by 1779.98% in 2025.
  • Century Therapeutics' Accumulated Expenses (Quarter) stood at $9.8 million in 2022, then grew by 3.13% to $10.1 million in 2023, then soared by 72.05% to $17.5 million in 2024, then plummeted by 36.71% to $11.1 million in 2025.
  • Its Accumulated Expenses stands at $11.1 million for Q3 2025, versus $11.7 million for Q2 2025 and $10.9 million for Q1 2025.